



## UNDERSTANDING YOUR TREATMENT



# SS-31 (Elamipretide)

A mitochondria-targeted peptide studied for cellular energy optimization and cardioprotection.

- i** SS-31 (elamipretide) is a mitochondrially-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH<sub>2</sub>) that selectively binds cardiolipin on the inner mitochondrial membrane. FDA-approved as FORZINITY (September 2025, accelerated approval) for improving muscle strength in Barth syndrome patients  $\geq 30$  kg — the first

## HOW IT WORKS

**1****Compound Class**

Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)

**2****Mechanism**

Binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain function and reducing reactive oxygen species

**3****Research Focus**

Mitochondrial dysfunction, heart failure, age-related decline, exercise performance, neuroprotection

**Talk to your prescriber about whether SS-31 (Elamipretide) may be right for you**

This compound is available by prescription only



## WHAT RESEARCHERS HAVE FOUND

### Heart Failure (EMBRACE trial)

In the EMBRACE-STEMI trial, elamipretide reduced infarct size and improved cardiac function markers when administered during acute myocardial infarction.

*Circulation: Heart Failure, 2019*

### Barth Syndrome

Phase 2 data showed elamipretide improved 6-minute walk test distance and cardiac stroke volume in Barth syndrome patients with mitochondrial cardiomyopathy.

*Genetics in Medicine, 2021*

## QUESTIONS TO ASK YOUR PROVIDER

- ? What evidence level supports SS-31 (Elamipretide) for this patient's indication?
- ? What monitoring protocol should I establish?
- ? Are there contraindications or interactions to screen for?
- ? What is the recommended duration and cycling protocol?
- ? What is the current regulatory status?

## IMPORTANT SAFETY INFO

SS-31 has been studied in multiple Phase 2/3 clinical trials with generally acceptable safety profiles

Most common side effects in trials include injection site reactions and transient headache

Long-term safety data in non-trial settings are limited

Not yet FDA-approved — regulatory status varies by indication and region

Patients with severe mitochondrial disease should use only under specialist supervision

### Have Questions?

## Eternal Beauty Medical Aesthetics

9032789566

<https://www.eternalbeautytexarkana.com>

This is a compounded preparation and is NOT an FDA-approved product. It is prepared by a licensed pharmacy based on a prescription from your healthcare provider. The safety and efficacy of this compounded preparation have not been established by the FDA.